iRhythm Holdings has completed its acquisition of VitalConnect, expanding its cardiac monitoring platform across ambulatory, inpatient, remote and hospital-to-home care.
The purchase consideration included $237.5 million in cash, subject to customary adjustments, funded from iRhythm’s balance sheet, along with up to 423,334 shares issued at closing.
iRhythm also provided VitalConnect with $10 million of working capital funding between the signing and closing of the transaction.
VitalConnect adds mobile cardiac telemetry, wearable biosensors and multi-vital monitoring capabilities to iRhythm’s existing end-to-end cardiac monitoring platform.
Its technology supports multiple monitoring modalities and includes capabilities such as up to 30 days of patient monitoring, four-in-one functionality, flexible service models and live look-in.
The VitalConnect platform can monitor as many as 11 physiological parameters, expanding iRhythm’s strategy beyond traditional ambulatory cardiac monitoring.
iRhythm plans to combine these capabilities with its existing commercial scale, health system relationships, market-access expertise and integrated clinical services.
The acquisition immediately expands iRhythm’s presence in mobile cardiac telemetry and gives the company a broader portfolio for different clinical workflows and patient needs.
It also extends the company’s addressable market into inpatient, remote and hospital-to-home settings.
iRhythm expects the combination of the companies’ technology, data and workflows to accelerate innovation while creating cross-selling and customer-expansion opportunities.
Financially, the transaction is expected to enhance iRhythm’s revenue growth rate beginning in 2027.
The company continues to target a 15% adjusted EBITDA margin for 2027 despite the acquisition.
iRhythm plans to provide updated 2026 financial guidance incorporating VitalConnect during its third-quarter earnings call on November 5, 2026.
KEY QUOTES:
“Today marks an important milestone as iRhythm continues its evolution toward a broader cardiac monitoring and intelligence platform. VitalConnect brings complementary mobile cardiac telemetry (MCT), multi-vitals and monitoring capabilities to iRhythm’s established end-to-end cardiac monitoring service. Together, we can offer clinicians greater choice, serve more patients and customers across the continuum of care, and deepen customer relationships. We are pleased to welcome the VitalConnect team to iRhythm.”
Quentin Blackford, President and Chief Executive Officer of iRhythm
“Joining iRhythm creates an opportunity to extend the reach and impact of VitalConnect’s technology. By bringing together what our team has built with iRhythm’s scale, clinical expertise and customer reach, we believe we can accelerate the growth of our platform, expand access to our technology and create even greater value for clinicians and patients.”
Peter Van Haur, Chief Executive Officer of VitalConnect
